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A major aim in studying any signal transduction process is
to generate a quantitative depiction of that process that is
both biologically and physically realistic. The ensuing
model then serves as an explicit hypothesis whose predi-
cations can be subjected to direct experimental test and
(ideally) also a framework for interpreting new data.
Although this approach has been fundamental to gaining
an understanding of related signalling mechanisms (e.g.
neurotransmission at brain synapses), no such model
presently exists for NO signal transduction through its
guanylyl cyclase-coupled receptors, despite an abundance
of experimental data published during the past three dec-
ades. The objective was to assemble the existing informa-
tion, together with results from necessary new
experiments, into a comprehensive and overt description
of how this system works. An essential first step was to
combine an NO-binding module with a catalytic site
where, following a conformational change, GTP is con-
verted into cGMP. The NO binding module is a cubic ter-
nary complex mechanism analogous to the one adopted
for G protein-coupled receptors [1]. Catalysis is assumed
to follow a mechanism similar to that found for adenylyl
cyclase [2]. After allocating rates (or equilibrium con-
stants) to the various steps, constrained to fit experimen-
tal results, the resulting hybrid mechanism faithfully
describes the basic features of NO activation of guanylyl
cyclase and provides explanations for some puzzling pub-
lished results. The core mechanism has been elaborated to
include inhibition by ATP [3] and allosteric enhancement
by compounds such as YC-1 and BAY 41–2272 [4].
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